Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
BioCardia, Inc. logo — a leader in the development of comprehensive solutions for c...

BioCardia, Inc.

a leader in the development of comprehensive solutions for cardiovascular regenerative therapies

Founded 2002 United States Sunnyvale, United States 24 employees Post-IPO Equity Biotechnology, Health and Wellness

General Information

Company Name BioCardia, Inc.
Founded Year 2002
Location United States Sunnyvale, United States
Founders / Decision Makers
Team member
Employees 24
Industries Biotechnology, Health and Wellness
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with BioCardia, Inc.. To contact BioCardia, Inc., visit biocardia.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does BioCardia, Inc. compare?

A PDF of BioCardia, Inc. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting BioCardia, Inc. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About BioCardia, Inc.

BioCardia, Inc. is a clinical-stage regenerative medicine company founded in 2002, specializing in the development of novel therapeutics for cardiovascular diseases. The company's slogan, "a leader in the development of comprehensive solutions for cardiovascular regenerative therapies," reflects its commitment to addressing large unmet medical needs in this field. BioCardia's proprietary biotherapeutic solutions, CardiAMP™ and CardiALLO™ therapies, have shown compelling clinical results, supported by rigorous data in the field, particularly with intramyocardial delivery of marrow-derived cells. These advancements are made possible by the company's Helix™ transendocardial delivery systems and Morph® vascular access products, which enable the development of other promising biotherapeutic programs. The last investment in BioCardia, Inc. was a Post-IPO Equity investment on 30 August 2024. The investors involved in this latest round of funding are currently undisclosed. The company operates within the biotechnology and health and wellness industries, positioning itself as a significant player in the cardiovascular regenerative therapies market. With its innovative therapies and strong clinical results, BioCardia is well-positioned to continue making strides in addressing unmet medical needs in cardiovascular diseases.

Business keywords: regenerative medicine, cardiovascular therapy, clinical-stage research, therapeutics development, transendocardial delivery systems, vascular access products

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity Undisclosed -
30 Aug 2024
Post IPO Equity Undisclosed -
16 Nov 2023
Post IPO Equity Undisclosed -
15 Dec 2022
Post IPO Equity Undisclosed -
16 Dec 2020
Post IPO Equity Undisclosed -
17 Jun 2020
Venture Series Unknown Undisclosed -
30 Jun 2008

BioCardia, Inc. Alternatives & Competitors

View All Alternatives
BioCardia, Inc. vs
Juventas Therapeutics
Juventas Therapeutics

Pioneering regenerative therapies for life-threatening diseases with a robust clinical pipeline and...

Series B
Biotechnology, Health Care
BioCardia, Inc. vs
Pantherna Therapeutics GmbH
Pantherna Therapeutics GmbH Germany

Developing novel mRNA-based therapeutics

Seed
11 employees
Biotechnology, Health Care
BioCardia, Inc. vs
Aegle Therapeutics
Aegle Therapeutics United States

Developing extracellular vesicle (EV) therapies to address rare and serious diseases and disorders

Convertible Note
7 employees
Biotechnology, Health and Wellness
View all alternatives

FAQ About BioCardia, Inc.

a leader in the development of comprehensive solutions for cardiovascular regenerative therapies
BioCardia, Inc. was founded in 2002.
BioCardia, Inc. is headquartered in Sunnyvale, United States.
BioCardia, Inc. operates in Biotechnology and Health and Wellness. Its work centres on regenerative medicine, cardiovascular therapy, clinical-stage research and therapeutics development.
BioCardia, Inc. has approximately 24 employees.
BioCardia, Inc. has completed 6 funding rounds. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to BioCardia, Inc. include Juventas Therapeutics, Pantherna Therapeutics GmbH, Aegle Therapeutics, Longeveron Inc, HuidaGene Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
BioCardia, Inc. and Juventas Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for BioCardia, Inc., https://bouncewatch.com/company/biocardia-inc, updated 4 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout